

Vermont Commercial ACO Pilot

2014 Benchmarks

Statewide baseline data and benchmarks for each of the payment measures for the first measurement year of the Commercial ACO Pilot, CY2014, appear below.

#	Measure and Source	Proxy for Statewide Baseline ¹ 2012 BCBSVT (VHP) Performance	Benchmark 2012 HEDIS PPO
Core-1	Plan All-Cause Readmissions <i>Source: NQF #1768, HEDIS PCR</i>	0.7309 Nat: 50 th	3 pt: Nat. 75 th : 0.73 2 pt: Nat. 50 th : 0.78 1 pt: Nat. 25 th : 0.83 <i>Please note, when interpreting this measure, a lower rate is better.</i>
Core-2	Adolescent Well-Care Visits <i>Source: HEDIS AWC (Not NQF endorsed)</i>	49.57 Nat.: 75 th	3 pt: Nat. 75 th : 46.32 2 pt: Nat. 50 th : 38.66 1 pt: Nat. 25 th : 32.14
Core-3	Cholesterol Management for Patients with Cardiovascular Conditions (LDL-C Screening Only for Year 1) ² <i>Source: HEDIS CMC (Not NQF endorsed)</i>	88.95 Nat.: 75 th	3 pt: Nat. 75 th : 87.94 2 pt: Nat. 50 th : 84.67 1 pt: Nat. 25 th : 81.27
Core-4	Follow-Up After Hospitalization for Mental Illness: 7-day <i>Source: NQF #0576, HEDIS FUH</i>	72.31 Nat.: 90 th	3 pt: Nat. 75 th : 60.00 2 pt: Nat. 50 th : 53.09 1 pt: Nat. 25 th : 45.70

¹ Actual statewide baseline performance cannot be calculated until ACO attribution has been finalized.

² Core-3 is counted in both the “payment” and “pending” categories since the claims-based HEDIS measures “Cholesterol Management for Patients with Cardiovascular Conditions” (LDL-screening only) will be used for payment until the clinical data-based Complete Lipid Panel and LDL Control are ready to be used for payment, at which point, it will replace LDL screening.

#	Measure and Source	Proxy for Statewide Baseline ¹ 2012 BCBSVT (VHP) Performance	Benchmark 2012 HEDIS PPO
Core-5	Initiation and Engagement for Substance Abuse Treatment: Initiation and Engagement of AOD Treatment (composite) <i>Source: NQF #0004, HEDIS IET</i>	26.54 Nat.: 25 th	3 pt: Nat. 75 th : 31.94 2 pt: Nat. 50 th : 27.23 1 pt: Nat. 25 th : 24.09
Core-6	Avoidance of Antibiotic Treatment for Adults With Acute Bronchitis <i>Source: NQF #0058, HEDIS AAB</i>	19.69 Nat.: 25 th	3 pt: Nat. 75 th : 24.30 2 pt: Nat. 50 th : 20.72 1 pt: Nat. 25 th : 17.98
Core-7	Chlamydia Screening in Women <i>Source: NQF #0033, HEDIS CHL</i>	45.57 Nat.: 50 th	3 pt: Nat. 75 th : 47.30 2 pt: Nat. 50 th : 40.87 1 pt: Nat. 25 th : 36.79

Core Measure 5, the Initiation and Engagement for Substance Abuse Treatment composite measure, is comprised of two components below. The national benchmarks above were created by taking the average of the two components for the percentiles at each level. Likewise, the Commercial composite performance was determined by taking the average performance of the two components below.

#	Measure and Source	Proxy for Statewide Baseline 2012 BCBSVT (VHP) Performance	Benchmark 2012 HEDIS PPO
Core-5a	Initiation and Engagement for Substance Abuse Treatment: Initiation of AOD Treatment <i>Source: NQF #0004, HEDIS IET</i>	34.17	Nat. 75 th : 45.93 Nat. 50 th : 40.08 Nat. 25 th : 36.45

#	Measure and Source	Proxy for Statewide Baseline 2012 BCBSVT (VHP) Performance	Benchmark 2012 HEDIS PPO
Core-5b	Initiation and Engagement for Substance Abuse Treatment: Engagement of AOD Treatment. <i>Source: NQF #0004, HEDIS IET</i>	18.91	Nat. 75 th : 17.95 Nat. 50 th : 14.38 Nat. 25 th : 11.72